Hoth Therapeutics And Silo Pharma Form Strategic JV To Develop, Commercialize Treatment For Obesity, Metabolic Disease Based On Technology Exclusively Licensed From U.S. Department Of Veterans Affairs

Author: Benzinga Newsdesk | June 25, 2025 07:29am

*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market

Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease

NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) and Silo Pharma, Inc. (NASDAQ:SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA).

The novel therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and central obesity.

Deal Highlights:

• Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use
• 50/50 Joint Venture structure with equal equity and governance participation 
• Lead Indication: Obesity and NAFLD 

Posted In: HOTH SILO